OR-USB-IF
27.5.2021 00:02:07 CEST | Business Wire | Press release
The USB Promoter Group today announced the release of the USB Power Delivery (USB PD) Revision 3.1 specification, a major update to enable delivering up to 240W of power over the USB Type-C® cable and connector. Prior to this update, USB PD was limited to 100W via a solution based on 20V using USB Type-C cables rated at 5A. The USB Type-C specification has also been updated with Release 2.1 to define 240W cable requirements, and with the updated USB PD protocol and power supply definition, this extends the applicability of USB PD to a large number of applications where 100W wasn’t adequate.
The new USB PD architecture defines a much more stringent power negotiation protocol that helps to ensure that access to and use of this higher power capability can be done safely. It should be noted that safety requirements for products that use power in the range of 100 – 240W are also more stringent than lower power products and are defined by the applicable safety specifications dictated by the regulations for each country where the products will be sold.
“With the new capabilities of USB Power Delivery 3.1, we now enable higher power products such as larger notebook PCs to shift from traditional power connectors to USB Type-C,” said Brad Saunders, USB Promoter Group Chairman. “We also anticipate a wider range of product application developers outside of the traditional USB ecosystem to now consider standardizing on USB Type-C with USB PD power their power needs.”
Key characteristics of the USB PD 3.1 specification include:
- A choice of three new fixed voltages: 28V (above 100W), 36V (above 140W) and 48V (above 180W) joining previously defined 5V, 9V, 15V and 20V fixed voltages.
- A new adjustable voltage mode enabling a range from 15V to one of three maximum voltages (28V, 36V, or 48V) depending on the available power allowing the device being powered to request specific voltages to a 100 mV resolution.
USB Developer Days 2021, in the second half of this year, will include detailed technical training covering the updated USB PD and USB Type-C specifications.
This update is part of the USB performance roadmap and is specifically targeted to developers at this time. Branding and marketing guidelines are being established and will include a new cable labeling solution to inform users of the power capability supported by Certified USB Type-C cables.
“Always responsive to the market’s need for a higher-power, truly universal bus connector, the USB Promoter Group has again been quick to recognize and adapt its specifications for charging capability to anticipate customer requirements, potentially creating new markets for USB Power Delivery. ST, as an active member of the USB Promoter Group, with its strong company legacy of cooperation, technical expertise, and product reliability, will continue to provide high-quality, optimized semiconductor solutions,” said Matteo Lo-Presti, Executive Vice President, Analog, Sub-Group General Manager, Analog MEMS, and Sensors Group, STMicroelectronics.
“The 3.1 revision to the USB Power Delivery specification, which includes the capability to provide up to 48 V and 240 W of power, will help enable additional design opportunities for current and new users of USB Type-C technology,” said Deric Waters, senior member of technical staff at Texas Instruments.
About the USB Promoter Group
The USB Promoter Group, comprised of Apple Inc., Hewlett-Packard Inc., Intel Corporation, Microsoft Corporation, Renesas Electronics Corporation, STMicroelectronics, and Texas Instruments, continues to develop the USB family of specifications to meet the market needs for increased functionality and performance of USB solutions. Additionally, the USB Promoter Group develops specification addendums (USB Power Delivery, USB Type-C®, and others) to extend or adapt its specifications to support more platform types or use cases where adopting USB technology will be beneficial in delivering a more ubiquitous, richer user experience.
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org .
USB Type-C® and USB-C® are registered trademarks of USB Implementers Forum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526006131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom